LRRK2 and Parkinson disease: A recent epidemiological study has proposed that the regular use of non-steroidal anti-inflammatory drugs (NSAIDs) that inhibit COX-2 could reduce the risk of PD in carriers of both pathogenic and risk variants of LRRK2 [69], suggesting a link between LRRK2 and COX-2 in PD pathogenesis.